<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323374</url>
  </required_header>
  <id_info>
    <org_study_id>Droxidopa FMS201</org_study_id>
    <nct_id>NCT01323374</nct_id>
  </id_info>
  <brief_title>Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia</brief_title>
  <acronym>FMS201</acronym>
  <official_title>A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Response, Study To Assess The Clinical Benefit Of Droxidopa and Droxidopa/Carbidopa In Subjects With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chelsea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chelsea Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A correlation between increased norepinephrine concentration in the central nervous system
      (CNS) and a decrease in fibromyalgia pain has been suggested in clinical studies. Therefore,
      as a pro-drug of norepinephrine, droxidopa could potentially benefit fibromyalgia patients by
      reducing pain as a result of increasing CNS levels of norepinephrine.

      As this benefit is presumed to be a central effect, the addition of carbidopa, a peripheral
      DOPA decarboxylase (DDC) inhibitor, may favorably impact the drug's treatment profile.
      Carbidopa is utilized as a blocker of peripheral DDC, an enzyme required for the conversion
      of droxidopa into norepinephrine. Therefore, inhibition of peripheral DDC should result in a
      reduction of any side effects resulting from the peripheral production of norepinephrine,
      whilst allowing for increased central levels, and hence, increased centrally mediated
      benefits.

      The purpose of the study is the obtain information regarding the proper dosing, effectiveness
      and safety of droxidopa and combination droxidopa/carbidopa treatments in patients with
      fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fibromyalgia syndrome (FMS) and Chronic widespread pain (CWP) are two syndromes within a
      broader class known as functional somatic syndromes. Chronic widespread pain (CWP) is defined
      according to the American College of Rheumatology (ACR), as pain both above and below the
      waist involving both sides of the body and lasting for at least 3 months. Fibromyalgia
      syndrome (FMS), a subset of CWP, is a multisystem disease characterized by sleep disturbance,
      fatigue, headache, morning stiffness, paresthesias, and anxiety.

      While there is debate as to specific etiology and pathogenesis, fibromyalgia is generally
      believed to be the result of a perturbation of central pain processing, specifically the
      neuroendocrine system. Fibromyalgia patients have been shown to have lower levels of
      metabolites from three neurotransmitters (serotonin, norepinephrine, and dopamine) in their
      cerebrospinal fluid (CSF) compared to healthy controls. The low rate of turnover of these
      neurotransmitters supports the hypothesis of a metabolic defect in fibromyalgia and suggests
      that the defect occurs at a neuroregulatory level. Results of a study that examined the
      effect of a permanent reduction in the noradrenergic innervation of the spinal cord suggested
      that the antinociceptive effects of norepinephrine are closely linked to opioidergic and
      tachykinergic neurotransmission.

      Droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the
      International non-proprietary name (INN) for a synthetic amino acid precursor of
      norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited,
      Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve
      symptoms of orthostatic hypotension that result from a variety of conditions including Shy
      Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease.
      There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is
      biologically active. Data from clinical studies and post-marketing surveillance programs
      conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa
      are increased blood pressure, nausea, and headache. In clinical studies to date, data
      suggests that droxidopa is well-tolerated and effective as a norepinephrine precursor.

      Pre-clinical and clinical studies suggest that droxidopa has an analgesic effect in patients
      with chronic pain. An increase in central nervous system (CNS) levels of norepinephrine has
      been shown to correlate with an analgesic effect. Based on the pre-clinical and clinical
      findings to date, it is hypothesized that droxidopa can provide pain reduction in
      fibromyalgia patients through increasing the CNS levels of norepinephrine.

      Carbidopa is a DOPA decarboxylase (DDC) inhibitor. At therapeutic doses carbidopa does not
      cross the blood-brain barrier and therefore should not inhibit CNS metabolism of droxidopa to
      NE. Decreasing the activity of DDC in the periphery enables droxidopa metabolism to be
      focused in the CNS. This CNS focus should increase CNS response while also limiting the
      increase in blood pressure associated with peripheral droxidopa metabolism. In addition, as
      DDC is an enzyme required for the conversion of droxidopa into its active metabolite
      norepinephrine, inhibition of peripheral DDC, utilizing Carbidopa, should result in a
      reduction of any side effects resulting from the peripheral production of NE, whilst allowing
      for increased central levels, and hence, increased centrally mediated benefits.

      The primary objective of this study is to determine the efficacy of droxidopa and
      droxidopa/carbidopa in the treatment of pain associated with fibromyalgia. Secondary
      objectives include: evaluation of the effect of droxidopa and combinations of
      droxidopa/carbidopa on signs and symptoms of fibromyalgia, evaluation of the effect of
      droxidopa and combinations of droxidopa/carbidopa on the overall quality of life of
      fibromyalgia patients, evaluation of the dose-response relationship for droxidopa between
      different doses of droxidopa, carbidopa and combinations of droxidopa/carbidopa in
      fibromyalgia patients, evaluation of the clinical benefit of treatment with different doses
      of droxidopa, carbidopa and combinations of droxidopa/carbidopa in fibromyalgia patients,
      estimation of the optimal dose for relief of fibromyalgia pain using response surface
      methodology, and evaluation of the safety of droxidopa and droxidopa/carbidopa treatments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the efficacy of droxidopa and droxidopa/carbidopa in the treatment of pain associated with fibromyalgia</measure>
    <time_frame>Baseline to end of 8 week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of droxidopa and combinations of droxidopa/carbidopa on signs and symptoms of fibromyalgia (including depression, fatigue, and sleep disorder)</measure>
    <time_frame>Baseline to end of 8 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of droxidopa and combinations of droxidopa/carbidopa on the overall quality of life of fibromyalgia patients</measure>
    <time_frame>Baseline to end of 8 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the dose-response relationship for droxidopa (200, 400, and 600mg TID), carbidopa (25 and 50mg TID) and combinations of droxidopa/carbidopa (200/25, 200/50, 400/25, 400/50, 600/25 and 600/50mg TID) in the treatment of fibromyalgia patients</measure>
    <time_frame>Baseline to end of 8 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the clinical benefit of treatment with 200, 400, and 600mg droxidopa TID, or 25 and 50mg carbidopa TID and combinations of droxidopa/carbidopa 200/25, 200/50, 400/25, 400/50, 600/25 and 600/50mg TID in the treatment of fibromyalgia patients</measure>
    <time_frame>Baseline to end of 8 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the optimal dose for relief of fibromyalgia pain using response surface methodology</measure>
    <time_frame>Baseline to end of 8 week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of droxidopa and droxidopa/carbidopa treatments based on the occurrence of treatment-emergent adverse events (AE) and specific evaluation of blood pressure, heart rate, ECG, and laboratory findings across the study.</measure>
    <time_frame>Baseline to end of 4 week follow-up period following 8 week treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Droxidopa 200mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa 400mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa 600mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbidopa 25mg TID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbidopa 50 mg TID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa/carbidopa 200mg/25mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa/carbidopa 400mg/25mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa/carbidopa 600mg/25mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa/carbidopa 200mg/50mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa/carbidopa 400mg/50mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Droxidopa/carbidopa 600mg/50mg TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo TID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droxidopa</intervention_name>
    <description>Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.</description>
    <arm_group_label>Droxidopa 200mg TID</arm_group_label>
    <arm_group_label>Droxidopa 400mg TID</arm_group_label>
    <arm_group_label>Droxidopa 600mg TID</arm_group_label>
    <other_name>L-threo-3,4-dihydroxyphenylserine</other_name>
    <other_name>L-threo-DOPS</other_name>
    <other_name>L-DOPS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa</intervention_name>
    <description>Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.</description>
    <arm_group_label>Carbidopa 25mg TID</arm_group_label>
    <arm_group_label>Carbidopa 50 mg TID</arm_group_label>
    <other_name>Lodosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Droxidopa/carbidopa</intervention_name>
    <description>Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.</description>
    <arm_group_label>Droxidopa/carbidopa 200mg/25mg TID</arm_group_label>
    <arm_group_label>Droxidopa/carbidopa 400mg/25mg TID</arm_group_label>
    <arm_group_label>Droxidopa/carbidopa 600mg/25mg TID</arm_group_label>
    <arm_group_label>Droxidopa/carbidopa 200mg/50mg TID</arm_group_label>
    <arm_group_label>Droxidopa/carbidopa 400mg/50mg TID</arm_group_label>
    <arm_group_label>Droxidopa/carbidopa 600mg/50mg TID</arm_group_label>
    <other_name>L-threo-3,4-dihydroxyphenylserine / Lodosyn</other_name>
    <other_name>L-threo-DOPS / Lodosyn</other_name>
    <other_name>L-DOPS / Lodosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral, placebo TID</description>
    <arm_group_label>Placebo TID</arm_group_label>
    <other_name>Inactive ingrediant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female and aged 18 years or over

          -  Clinical diagnosis of fibromyalgia as defined by the 1990 American College of
             Rheumatology (ACR) criteria

          -  Provide written informed consent to participate in the study and understand that they
             may withdraw their consent at any time without prejudice to their future medical care

          -  Have a score of between 20mm and 90mm on the Visual Analog Scale for Pain (VAS-P)
             section of the SF-MPQ at screening and baseline visits

        Exclusion Criteria:

          -  Have uncontrolled hypertension (defined as systolic blood pressure &gt;160 mmHg and/or
             diastolic blood pressure &gt;110 mmHg) or use of â‰¥2 antihypertensive medications

          -  Patients currently taking pregabalin; unless they provide written informed consent and
             agree to discontinue pregabalin use 3 weeks prior to other screening procedures and
             for the duration of the study

          -  Currently taking tri-cyclic antidepressant medication

          -  Currently taking any norepinephrine re-uptake inhibitors

          -  Have clinically relevant depression noted as significant by a score greater than 17 on
             the Hamilton Depression Scale (HAM-D)

          -  History of known or suspected drug or substance abuse

          -  Women of childbearing potential who are not using a medically accepted contraception
             (Reproductive potential: Female subjects should be either post-menopausal (amenorrhea
             for at least 12 consecutive months), surgically sterile, or women of child-bearing
             potential (WOCP) who are using or agree to use acceptable methods of contraception
             throughout the study period and for 4 weeks after the last dose of investigational
             product. Acceptable contraceptives include intrauterine devices (IUDs), hormonal
             contraceptives (oral, depot, patch or injectable) and double barrier methods such as
             condoms or diaphragms with spermicidal gel or foam. If hormonal contraceptives are
             used they should be taken according to the package insert. WOCP who are not currently
             sexually active must agree to use acceptable contraception, as defined above, if they
             decide to become sexually active during the period of the study and for 4 weeks after
             the last dose of investigational product. For WOCP a urine pregnancy test must be
             conducted at screening, baseline and study termination; the results must be negative
             at screening and at baseline. Any positive result will be confirmed by serum beta HCG
             pregnancy test).

          -  Sexually active males whose partner is a WOCP must agree to use condoms for the
             duration of the study and for 4 weeks after the last dose

          -  Women who are pregnant, breast feeding, or plan to become pregnant during the course
             of this study

          -  Known or suspected hypersensitivity to the study medication or any of its ingredients

          -  Have in the investigator's opinion any significant cardiac arrhythmia

          -  Any significant systemic, hepatic, cardiac or renal illness

          -  Diabetes mellitus or insipidus

          -  Have a history of closed angle glaucoma

          -  Have a known or suspected current malignancy. Patients with a history of cancer must
             be symptom- and treatment-free for at least 5 years prior to randomization, with the
             exception of patients with non-melanoma, non-invasive skin cancers (such as basal cell
             carcinoma), who should not have had an intervention or recurrence within one year of
             starting the study

          -  Patients with known gastrointestinal illness or other gastrointestinal disorder that
             may, in the investigator's opinion, affect the absorption of study drug

          -  In the investigator's opinion, have clinically significant abnormalities on clinical
             examination or laboratory testing

          -  In the investigator's opinion, are unable to adequately co-operate because of
             individual or family situation

          -  In the investigator's opinion, are suffering from a mental disorder that interferes
             with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major
             depression, dementia

          -  Are not able or willing to comply with the study requirements for the duration of the
             study

          -  Have participated in another clinical trial with an investigational agent (including
             named patient or compassionate use protocol) within 1 month before the start of the
             study

          -  Previous enrollment in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest Choy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Dept of Rheumatology Kings College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Department; Barnsley Hospital NHS Foundation Trust</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC UK Neuroscience</name>
      <address>
        <city>Liverpool</city>
        <zip>L18 1HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dept of Rheumatology, Kings College London</name>
      <address>
        <city>London</city>
        <zip>SE5 9RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC UK Neuroscience</name>
      <address>
        <city>Manchester</city>
        <zip>M32 0UT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musculoskeletal Department; Freeman Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Department, Poole Hospital NHS Trust</name>
      <address>
        <city>Poole</city>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Unit; Main Hospital; Salford Rooyal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>FMS</keyword>
  <keyword>droxidopa</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Droxidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

